Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

DISEASE CHARACTERISTICS: * Histologically confirmed lymphoproliferative disease * CD20-positive disease * Bidimensionally measurable disease OR abnormal cells detected in blood * Resistant or refractory to standard therapies and/or unlikely to benefit from additional standard therapies\* AND meets 1 of the following criteria: * Disease with anticipated response rate \< 20% after treatment with rituximab alone, including any of the following: * Diffuse large cell lymphoma * B-cell lymphoblastic lymphoma * Burkitt's lymphoma * Acute lymphocytic leukemia * Relapsed or progressive disease after prior treatment with rituximab, including any of the following: * Hodgkin's lymphoma * Hairy cell leukemia * Chronic lymphocytic leukemia/small lymphocytic lymphoma meeting any of the following criteria: * Received prior fludarabine phosphate-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies * Received prior anti-CD52 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy) * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment * B-cell prolymphocytic leukemia meeting any of the following criteria: * Received prior fludarabine phosphate- or alkylating agent-containing regimens and rela…